PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors

Activated B-cell-like diffuse large B-cell lymphoma relies on B-cell receptor signaling to drive proliferation and survival. Downstream of the B-cell receptor, the key signaling kinases Bruton’s tyrosine kinase and phosphoinositide 3-kinase δ offer opportunities for therapeutic intervention by agent...

Descripción completa

Detalles Bibliográficos
Autores principales: Yahiaoui, Anella, Meadows, Sarah A., Sorensen, Rick A., Cui, Zhi-Hua, Keegan, Kathleen S., Brockett, Robert, Chen, Guang, Quéva, Christophe, Li, Li, Tannheimer, Stacey L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5298344/
https://www.ncbi.nlm.nih.gov/pubmed/28178345
http://dx.doi.org/10.1371/journal.pone.0171221

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5298344/
https://www.ncbi.nlm.nih.gov/pubmed/28178345
http://dx.doi.org/10.1371/journal.pone.0171221

Ejemplares similares